Akero logo with white space 1.jpg
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
January 10, 2023 08:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 08:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
December 21, 2022 16:01 ET | Akero Therapeutics
Results of the main study in patients with compensated cirrhosis due to NASH (F4) expected in fourth quarter of 2023 Results of the cohort D expansion to evaluate EFX in combination with GLP-1...
Akero logo with white space 1.jpg
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
December 08, 2022 07:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
November 10, 2022 16:05 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
November 07, 2022 07:30 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 04, 2022 07:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
October 11, 2022 16:01 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
September 19, 2022 16:01 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
September 14, 2022 20:07 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...